1,2,4-Oxadiazoles Identified by Virtual Screening and their Non-Covalent Inhibition of the Human 20S Proteasome

Author(s): X. Maréchal, E. Genin, L. Qin, O. Sperandio, M. Montes, N. Basse, N. Richy, M.A. Miteva, M. Reboud-Ravaux, J. Vidal, B.O. Villoutreix

Journal Name: Current Medicinal Chemistry

Volume 20 , Issue 18 , 2013

Become EABM
Become Reviewer


Although several constitutive proteasome inhibitors have been reported these recent years, potent organic, noncovalent and readily available inhibitors are still poorly documented. Here we used a structure- and ligand-based in silico approach to identify commercially available 1,2,4-oxadiazole derivatives as non-covalent human 20S proteasome inhibitors. Their optimization led to the newly synthesized compound 4h that is a mixed proteasomal inhibitor of the chymotrypsin- like activity (Ki of 26,1 nM and K’i of 7.5 nM) which is in addition selective versus the challenging cathepsin B and calpain proteases. Molecular modelling studies corroborated the mechanism of inhibition and suggest an unusual binding of the inhibitor within the S5 binding pocket (β6 subunit). The cellular effects of our compounds validate their utility as potential pharmacological agents for anti-cancer pre-clinical studies.

Keywords: Chymotrypsin-like subsite S5 binding, cytotoxicity, non-covalent inhibitors, oxadiazoles, proteasome, virtual screening.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [2351 - 2362]
Pages: 12
DOI: 10.2174/0929867311320180006

Article Metrics

PDF: 74